Autres langues Protalix BioTherapeutics, Inc. TEL AVIV STOCK EXCHANGE

Actions

PLX

US74365A3095

Produits pharmaceutiques

Temps Différé TEL AVIV STOCK EXCHANGE 16:24:48 21/03/2023			Varia. 5j.	Varia. 1 janv.
732,50 ^ILa	-.--%		+3,29 %	+69,68 %

12/08	Transcript : Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026
12/08	Protalix BioTherapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

08/09	Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
12/08	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
12/08	Protalix: Q2 Earnings Snapshot
12/08	Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
12/08	Protalix BioTherapeutics, Inc. Reaffirms Earnings Guidance for the Year 2026
05/08	Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
13/05	Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
13/05	Protalix BioTherapeutics : PLX Corporate Presentation (May 2026)
13/05	Protalix: Q1 Earnings Snapshot
13/05	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
13/05	Protalix BioTherapeutics, Inc. Reaffirms Revenue Guidance for the Year 2026
06/05	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
08/04	La historia de la semana: ¿Por qué el mercado bursátil israelí resiste tan bien?
19/03	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announces European Commission Approval of an Add-On Every Four Weeks Dosing Regimen for Pegunigalsidase Alfa
18/03	Top Midday Decliners
18/03	Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
18/03	Protalix BioTherapeutics, Inc. Provides Earnings Guidance for the Year 2026
18/03	Protalix Biotherapeutics reports fiscal year 2025 financial and business results
18/03	Protalix: Q4 Earnings Snapshot
18/03	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
11/03	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
09/03	EU approves four-week dosing option for Chiesi and Protalix's Elfabrio
09/03	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
09/03	Chiesi Global Rare Diseases and Protalix Biotherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio
04/03	Ellomay Capital Ltd. Announces Board and Committee Changes